Aurobindo receives approval in Citalopram oral solution

16108 Investors following Aurobindo Pharm. Share this News with them.

0

Like this story, share it with millions of investors on M3

Aurobindo receives approval in Citalopram oral solution

Aurobindo receives yet another approval in Citalopram oral solution

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Aurobindo’s expertise excels in packaging too Aurobindo receives MCC South Africa’s approval for unit XII MCC South Africa approves 4 products Aurobindo gets 2nd UK MHRA approval in Mirtazapine tablets Aurobindo Pharma Q1 net profit up at Rs 36.2cr ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 25/05/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo pharma ltd is highly pleased to share that its product Citalopram oral solution 10mg/5ml has bagged USFDA approval. The company already has approval of Citalopram tablets of 10, 20, and 40mg strengths in tablet form.

Citalopram belongs to a class of medication called selective serotonin reuptake inhibitors (SSRIs). Citalopram is indicated in the treatment of depressive disorders.

This approval opens an opportunity of over 4mio USD market additionally to Aurobindo. Citalopram is a generic equivalent of Forest Laboratories' Celexa. With this Aurobindo has 30 of its products approved by USFDA, inclusive of tentative approvals.

Sourced From: Aurobindo Pharma Limited